Scalper1 News
Big biotech Regeneron Pharmaceuticals (REGN) beat analysts’ Q3 estimates and raised its guidance Wednesday, but the stock slid as expense guidance went up and newly launched cholesterol drug Praluent missed expectations. Regeneron’s earnings rose 37% over the year-earlier quarter to $3.47 a share, beatings analysts’ consensus by 27 cents, according to Thomson Reuters. Revenue climbed 57% to $1.14 billion, about $80 million above consensus. Scalper1 News
Scalper1 News